QSYMIA (Phentermine– topiramate), Drug Insight and Market Forecast – 2032

QSYMIA (Phentermine– topiramate), Drug Insight and Market Forecast – 2032

“QSYMIA (Phentermine – topiramate), Drug Insight and Market Forecast – 2032” report provides comprehensive insights about QSYMIA (Phentermine– topiramate) for Obesity in the 7MM. A detailed picture of the QSYMIA (Phentermine– topiramate) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the QSYMIA (Phentermine– topiramate) for Obesity. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the QSYMIA (Phentermine– topiramate) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

QSYMIA, previously known as Qnexa, is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial Body Mass Index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

The recommended dosage regimen of QSYMIA is 3.75 mg/23 mg (phentermine 3.75 mg/topiramate 23 mg extended-release) daily for 14 days; then increase to 7.5 mg/46 mg daily. Discontinue or escalate dosage if 3% weight loss is not achieved after 12 weeks on a 7.5 mg/46 mg dose or if 5% weight loss is not achieved after 12 weeks on a maximum daily dose of 15 mg/92 mg.

Phentermine is a sympathomimetic amine with pharmacologic activity similar to amphetamine (d- and d/l-amphetamine), the prototype drug of this class used in obesity. Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” The effect of phentermine on chronic weight management is likely mediated by the release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food consumption, but other metabolic effects may also be involved. The exact mechanism of action is not known.

The precise mechanism of action of topiramate on chronic weight management is not known. Topiramate’s effect on chronic weight management may be due to its effects on both appetite suppression and satiety enhancement, induced by a combination of pharmacologic effects, including augmenting the activity of the neurotransmitter gamma-aminobutyrate, modulation of voltage-gated ion channels, inhibition of AMPA/kainite excitatory glutamate receptors, or inhibition of carbonic anhydrase.

The precise mechanism of action of topiramate on chronic weight management is not known. Topiramate’s effect on chronic weight management may be due to its effects on both appetite suppression and satiety enhancement, induced by a combination of pharmacologic effects, including augmenting the activity of the neurotransmitter gamma-aminobutyrate, modulation of voltage-gated ion channels, inhibition of AMPA/kainite excitatory glutamate receptors, or inhibition of carbonic anhydrase.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the QSYMIA (Phentermine– topiramate) description, mechanism of action, dosage and administration, research and development activities in Obesity.

Elaborated details on QSYMIA (Phentermine– topiramate) regulatory milestones and other development activities have been provided in this report.

The report also highlights the QSYMIA (Phentermine– topiramate) research and development activity in Obesity in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around QSYMIA (Phentermine– topiramate).

The report contains forecasted sales of QSYMIA (Phentermine– topiramate) for Obesity till 2032.

Comprehensive coverage of the late-stage emerging therapies for Obesity.

The report also features the SWOT analysis with analyst views for QSYMIA (Phentermine– topiramate) in Obesity.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

QSYMIA (Phentermine– topiramate) Analytical Perspective by DelveInsight

In-depth QSYMIA (Phentermine– topiramate) Market Assessment

This report provides a detailed market assessment of QSYMIA (Phentermine– topiramate) in Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

QSYMIA (Phentermine– topiramate) Clinical Assessment

The report provides the clinical trials information of QSYMIA (Phentermine– topiramate) in Obesity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence QSYMIA (Phentermine– topiramate) dominance.

Other emerging products for Obesity are expected to give tough market competition to QSYMIA (Phentermine– topiramate) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of QSYMIA (Phentermine– topiramate) in Obesity.

Our in-depth analysis of the forecasted sales data of QSYMIA (Phentermine– topiramate) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the QSYMIA (Phentermine– topiramate) in Obesity.

Key Questions

What is the product type, route of administration and mechanism of action of QSYMIA (Phentermine– topiramate)?

What is the clinical trial status of the study related to QSYMIA (Phentermine– topiramate) in Obesity and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the QSYMIA (Phentermine– topiramate) development?

What are the key designations that have been granted to QSYMIA (Phentermine– topiramate) for Obesity?

What is the forecasted market scenario of QSYMIA (Phentermine– topiramate) for Obesity?

What are the forecasted sales of QSYMIA (Phentermine– topiramate) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Obesity and how are they giving competition to QSYMIA (Phentermine– topiramate) for Obesity?

Which are the late-stage emerging therapies under development for the treatment of Obesity?